Transplant tolerance: Progress and challenges

Journal of Nephrology

Volumn 23, Issue 3, 2010, Pages 263-270

  Casiraghi, Federica ^a   Aiello, Sistiana ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Dendritic cells; Memory T cells; Regulatory T cells; Tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; CALCINEURIN INHIBITOR; CD4 ANTIBODY; COLECALCIFEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; UNCLASSIFIED DRUG;

CANCER RISK; CELL THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; LONG TERM CARE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MEMORY T LYMPHOCYTE; MOLECULAR MECHANICS; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 77951731560     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Murray JE, Merrill JP, Harrison JH. Kidney transplantation between seven pairs of identical twins. Ann Surg. 1958;148:343-359.
2. Sayegh MH, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet. 2007;369:1676-1678.
3. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083-1091.
4. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol. 2000;20:126-147.
5. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
6. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 2001;108:943-948. (Pubitemid 32946066)
7. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003;3:147-158. (Pubitemid 37328692)
8. Remuzzi G, Perico N, Carpenter CB, Sayegh MH. The thymic way to transplantation tolerance. J Am Soc Nephrol. 1995;5:1639-1646.
9. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417-424.
10. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006;6:2121-2133. (Pubitemid 44199546)
11. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002;73:1386-1391. (Pubitemid 34547457)
12. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353-361. (Pubitemid 351159234)
13. Cavinato RA, Casiraghi F, Azzollini N, et al. Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. Transplantation. 2005;79:1034-1039. (Pubitemid 40663993)
14. Morita H, Sugiura K, Inaba M, et al. A strategy for organ allografts without using immunosuppressants or irradiation. Proc Natl Acad Sci U S A. 1998;95:6947-6952. (Pubitemid 28278087)
15. Bach JF. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease. C R Biol. 2006;329:260-262.
16. Waldmann H, Adams E, Fairchild P, Cobbold S. Regulation and privilege in transplantation tolerance. J Clin Immunol. 2008;28:716-725.
17. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol. 2008;38:901-937.
18. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-244. (Pubitemid 351267321)
19. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 2002;168:1080-1086. (Pubitemid 34094471)
20. Cavinato RA, Casiraghi F, Azzollini N, et al. Role of thymic and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. Kidney Int. 2007;71:1132-1141. (Pubitemid 46809139)
21. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933-3946.
22. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
23. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925-3932.
24. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271-275.
25. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-1265. (Pubitemid 46919862)
26. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109:2058-2065.
27. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566-569.
28. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7:610-621. (Pubitemid 47123548)
29. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol. 2000;30:1813-1822. (Pubitemid 30456177)
30. Tomasoni S, Aiello S, Cassis L, et al. Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. Transplantation. 2005;79:1056-1061. (Pubitemid 40663997)
31. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol. 2007;178:5480-5487. (Pubitemid 46674342)
32. Aiello S, Cassis P, Cassis L, et al. DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties. Transplantation. 2007;83:474-484. (Pubitemid 46667852)
33. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5:228-236. (Pubitemid 40179509)
34. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood. 2007;109:827-835.
35. Kirk AD. Induction immunosuppression. Transplantation. 2006;82:593-602.
36. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76:120-129.
37. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80:1051-1059.
38. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18:1007-1018. (Pubitemid 46434518)
39. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation. 2007;84:956-964. (Pubitemid 350287376)
40. Veronese F, Rotman S, Smith RN, et al. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant. 2007;7:914-922. (Pubitemid 46481190)
41. Grimbert P, Mansour H, Desvaux D, et al. The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation. 2007;83:341-346. (Pubitemid 46247867)
42. Martin L, Funes de la Vega M, Bocrie O, et al. Detection of Foxp3+ cells on biopsies of kidney transplants with early acute rejection. Transplant Proc. 2007;39:2586-2588. (Pubitemid 47588396)
43. Naka EL, Ponciano VC, Rangel EB, Cenedeze MA, Pacheco-Silva A, Camara NO. FOXP3-positive regulatory cells inside the allograft and the correlation with rejection. Transplant Proc. 2006;38:3202-3204. (Pubitemid 44908503)
44. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353:2342-2351. (Pubitemid 41713746)
45. Dijke IE, Caliskan K, Korevaar SS, et al. FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transpl Immunol. 2008;18:250-254. (Pubitemid 350151856)
46. Yang H, Ding R, Sharma VK, et al. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation. 2007;83:1643-1647. (Pubitemid 46987919)
47. Bunnag S, Allanach K, Jhangri GS, et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant. 2008;8:1423-1433. (Pubitemid 351989494)
48. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol. 2007;18:2252-2261. (Pubitemid 47203840)
49. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol. 1999;163:2267-2275. (Pubitemid 29382237)
50. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol. 2002;13:252-259. (Pubitemid 34042035)
51. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003;111:1887-1895.
52. Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol. 2002;169:3686-3693.
53. Curtsinger JM, Lins DC, Mescher MF. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J Immunol. 1998;160:3236-3243.
54. Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol. 2002;169:3760-3770.
55. Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol. 2000;164:2338-2346. (Pubitemid 30115460)
56. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol. 2000;164:265-272.
57. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 1994;152:2675-2685. (Pubitemid 24097962)
58. Khayyamian S, Hutloff A, Buchner K, et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci USA. 2002;99:6198-6203. (Pubitemid 34493289)
59. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5:465-474. (Pubitemid 40313337)
60. Gallon L, Gagliardini E, Benigni A, et al. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). Clin J Am Soc Nephrol. 2006;1:539-545.
61. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. Transplantation. 2006;82:1352-1361. (Pubitemid 44832918)
62. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unre-lated donors. N Engl J Med. 1995;333:333-336.
63. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008;86:889-894.
64. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Resident dendritic cells are the predominant TNFsecreting cell in early renal ischemia-reperfusion injury. Kidney Int. 2007;71:619-628. (Pubitemid 46494569)
65. Miller DM, Thornley TB, Greiner DL, Rossini AA. Viral infection: a potent barrier to transplantation tolerance. Clin Dev Immunol. 2008; 2008:742-810.
66. LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol. 2007;178:7503-7509. (Pubitemid 46898016)
67. Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am J Transplant. 2006;6:2282-2291. (Pubitemid 44359413)
68. Thornley TB, Brehm MA, Markees TG, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol. 2006;176:1561-1570.
69. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003;111:1571-1578. (Pubitemid 38063290)
70. Tesar BM, Zhang J, Li Q, Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein. Am J Transplant. 2004;4:1429-1439. (Pubitemid 39159057)
71. Chen X, Howard OM, Oppenheim JJ. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol. 2007;178:6123-6129. (Pubitemid 46717393)
72. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
73. Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005;309:1380-1384.
74. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006;103:7048-7053.
75. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974. (Pubitemid 47300011)
76. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957. (Pubitemid 47300009)
77. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-189. (Pubitemid 43214587)
78. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231-234.
79. Ashton-Chess J, Giral M, Brouard S, Soulillou JP. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation. 2007;84:1215-1219. (Pubitemid 351339307)
80. Girlanda R, Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans. J Am Soc Nephrol. 2007;18:2242-2251. (Pubitemid 47203839)
81. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation. 2006;81:398-407. (Pubitemid 43255726)
82. Braudeau C, Racape M, Giral M, et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int. 2007;20:845-855.
83. Mansour H, Homs S, Desvaux D, et al. Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol. 2008;19:2277-2281.